Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Zambon Launch Xadago in UK
Zambon S.p.A., an international pharmaceutical company committed to the CNS therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (Newron), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the CNS and pain, announced the availability of Xadago (safinamide) in the United Kingdom.
- Read more about Dr. Reddy ’ s enters the branded consumer health arena through the acquisition of six OTC brands
Hyderabad, India and Princeton, NJ, USA Dr.Reddy’s Laboratories Ltd.(BSE: 500124, NSE:DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over the counter (OTC) brands in the cough and cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN’S®, BUFFERIN®, NUPERCAINAL® Ointment, CRUEX ® Nail Gel, COMTREX ® , and MYOFLEX ®.
- Read more about CDSCO to start risk based inspection of the pharma manufacturing facilities
The role and responsibilities of the drug regulators have changed due to expansion and advent in pharmaceutical sciences. Now, their role is not limited only to issue permissions/licenses but to take a proactive role in ease of doing business in India.
- Read more about New study surveys genetic changes linked with Parkinson's disease
After Alzheimer's, Parkinson's disease (PD) is the leading neurodegenerative disorder, affecting close to a million Americans, with 50,000 new cases diagnosed every year. A progressive disorder of the nervous system affecting movement, PD typically strikes adults in mid-life. In many cases, the spread of the disease to other brain areas leads to Parkinson's disease dementia, characterized by deterioration of memory, reason, attention and planning.
- Read more about Chemo, radiation, surgery combo boosts survival for pancreatic cancer patients
In roughly one-third of pancreatic cancer patients, tumors have grown around the pancreas to encompass critical blood vessels. Conventional wisdom has long held that surgery to remove the tumors is rarely an option, and life expectancies are usually measured in months. Mayo Clinic, teaming oncologists, gastrointestinal and vascular surgeons and others, is finding that many of these patients actually are candidates for surgery. Mayo has been fine-tuning a protocol to treat them, and in two studies, found survival now stretching into years.
- Read more about Harnessing nature's vast array of venoms for drug discovery
Scorpions, snakes, snails, frogs and other creatures are thought to produce tens or even hundreds of millions of distinct venoms. These venoms have been honed to strike specific targets in the body.
- Read more about Allergan's BOTOX Vista® Receives National Marketing Authorisation in Japan
Allergan plc announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista® (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).
- Read more about Avantis Medical Systems Get FDA clearance for Resposable Third Eye® PanoramicTM Device
Avantis Medical Systems, Inc announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its Third Eye® Panoramic™ device for use as a resposable product for colonoscopies. Previously cleared as a disposable device, this latest clearance now allows Third Eye Panoramic to be marketed in the U.S. as a resposable device that can be used multiple times prior to disposal.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Egalet with Purdue Pharma Settles Patent Litigations
Egalet Corporation announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII.
- Read more about FDA’s made briefing documents on lixisenatide and the lixisenatide/Lantus® combination product
Zealand announces that the US Food and Drug Administration (FDA) has made briefing documents on lixisenatide and the lixisenatide/Lantus® combination available on its website. The documents relate to the upcoming meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, scheduled by the FDA for 8:00 am to 5:00 pm ET on 25 May 2016 to discuss the New Drug Applications (NDAs) for the two drug products intended for the treatment of adults with Type 2 diabetes. The NDAs were submitted by Sanofi.